Bayer Animal Health has launched Baytril® Max 100mg/ml Solution for Injection for Cattle and Pigs, which replaces the company's previously animal-specific Baytril Max products.
Bayer says the active ingredient, enrofloxacin, treats bacterial infection by inhibiting the action of bacterial DNA gyrase resulting in bacterial cell death.
In cattle, Baytril Max treats respiratory infections and mastitis caused by enrofloxacin-sensitive Histophilus somni, Mannheimia haemolytica, Pasteurella multocida and Mycoplasma spp., and enrofloxacin-sensitive E. coli respectively.
In pigs, Baytril Max targets bacterial bronchopneumonia caused by enrofloxacin-sensitive Actinobacillus pleuropneumoniae, Pasteurella multocida and complicated by Haemophilus parasuis as a secondary pathogen in pigs.
Bayer advises that vets treating cattle for respiratory infections should inject subcutaneously. Mastitis cases should be treated intravenously and pigs should be injected intramuscularly in the neck muscles, behind the ear.
The development of the Baytril Max product family provides vets with greater treatment flexibility from one solution.
For further information please visit www.noahcompendium.co.uk
Velactis (cabergoline) is a POM marketed by Ceva Animal Health, used in the herd management programme of dairy cows as an aid in abrupt drying-off, by reducing milk production.
The product was authorised through the European Medicines Agency (EMA) in December 2015 and was first sold in the UK in April 2016.
The VMD says it has been made aware of reports of serious adverse events, predominantly occurring in Denmark, involving recumbency (lying down and unable to rise) and some deaths. Most adverse events occurred within 8 to 24 hours following product administration. Anecdotal evidence suggests that hypocalcaemia treatments may be successful in reversing clinical signs.
Ceva has decided to stop further distribution of the product in Europe voluntarily, pending the outcome of further investigations to assess a possible causal link between the product and the adverse events reported.
The VMD, EMA, other agencies throughout Europe and the MAH are working closely to monitor the situation.
The VMD highlights that due to the nature and use of the product there is no risk to human health or consumer safety.
Vets and dairy farmers are strongly encouraged to report any adverse events associated with use of Velactis to the VMD using its online reporting form or directly to Ceva for further investigation by the MAH as necessary.
The BVA has expressed its concern that almost two-thirds of food companies have no information on their commitment to stunning animals before slaughter – with only 4% having a "universal commitment".
The findings were published in the Business Benchmark on Farm Animal Welfare report (BBFAW, published 27 January) and also show that slaughter without pre-stunning is the only welfare measure showing a decline in the percentage of food companies that have a specific policy on the practice, down from 34% in 2014 to 32% in 2015.
BVA has run a long-standing and high profile campaign to end non-stun slaughter in the UK, with a public petition in 2015 gaining 120,000 signatures. BVA, together with all leading farm animal welfare organisations, believes that all animals should be stunned before slaughter to render them insensible to pain. Scientific evidence supports the use of pre-stunning to safeguard animal welfare. In 2015, two-thirds of BVA members listed the issue as one of their top priorities for government.
BVA President Sean Wensley said: "Vets and the public are united in their concern about animal welfare at slaughter. There are several positive findings on the growing commitment of food companies towards farm animal welfare in the BBFAW report, which we welcome, but the report highlights a disappointing lack of commitment towards animal welfare at the time of slaughter. The European Commission’s study of 13,500 meat consumers across Europe found that 72% wanted information about the stunning of animals at slaughter. Food companies need to sit up and take consumers’ concerns about humane slaughter seriously. People want to be assured that farmed animals receive both a good life and a humane death."
Described as a first-of-its-kind, mobile-enabled digital whitepaper, the publication offers veterinary surgeons and farmers a resource on ketosis, scientific insights on the impact of the disease, and tools to help optimize dairy herd management.
According to the company, the whitepaper reveals that ketone bodies play a more significant role in metabolic diseases than was previously realized, and that beta-hydroxybutyrate is a good indicator of the presence of subclinical ketosis in dairy cattle.
Rinse Boersma, Dairy Species Manager, Animal Health, Bayer said: "Recognizing the significance of ketone bodies is a positive step towards further enhancing dairy cattle health and welfare. Veterinarians can now reliably detect the presence of subclinical ketosis in dairy herds with a simple blood test, and act quickly with the appropriate corrective measures to arrest disease progression."
Also at Congress, Bayer revealed its enhanced BCS Cowdition smartphone application, designed to support ease and accuracy of body condition scoring (BCS) of dairy cows. Bayer says the upgrade helps farmers to improve herd health management by enabling assessment of individual cows’ BCS scores based on its lactation cycle, alerts for cows that need to be attended to, and a dashboard that offers farmers an overview of their entire herd’s health.
BCS Cowdition is available in 10 languages and is free for download from the AppStore and GooglePlay.
CEVA Animal Health has launched Marbokem, a Marbofloxacin-based antimicrobial for the treatment of respiratory disease in cattle which offers the advantages of a one-shot protocol and a shock-resistant vial.
Marbokem is used for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica and Histophilus somni. CEVA says Marbofloxacin's efficacy has been proven in terms of re-treatment rate, success, speed of action and MICs in comparison with many frequently used quinolones and macrolides. (1,2,3,4)
According to CEVA, Marbokem's one shot protocol means it's quick and economical to use, while its presentation in an ergonomic CLAS vial makes for light and shock-resistant handling, resulting in fewer breakages and reduced costs. The company says Marbokem is also very competitively priced.
For further product information, please contact CEVA Animal Health Ltd, 90 The Broadway, Chesham, Bucks, HP5 1EG, telephone 01494 781510 or visit the website at http://www.ceva.uk.com/
1 Grandemange, E., Fournel, S., Woerhle, F. (2009) Field evaluation of the efficacy of 2 antibiotics in treating bovine respiratory infections. Poster, Journées Nationales des GTV, Nantes, France. 2. Grobbel, M., Lübke-Becker, A., Wieler, L., Froyman R., Friederichs, S., Filios, S. (2007) Comparative quantification of the in-vitro activity of veterinary fluoroquinolones. Veterinary microbiology 124 (73-81). 3. Roy, O., Pillet, F., Heurtin-Vallé, A., Frontczak, N. (2008) Comparative field clinical efficacy of a single intramuscular injection of marbofloxacin in the treatment of bovine respiratory disease. Poster, World Buiatrics Congress, Budapest, Hungary.4. Wu, C. (2004) Determination of minimum inhibitory concentrations of danofloxacin and other commonly used cattle antimicrobial agents against Mycoplasma bovis isolated from cattle with clinical disease. Le médecin vétérinaire du Québec. 34 (1-2).
The new methods, published in Applied and Environmental Microbiology, use a simple swabbing technique to gather samples from the environment which FMD-susceptible animals such as cattle, sheep and pigs commonly make contact with, such as water troughs.
Researchers say the technique requires very little expertise, which makes the sampling method far more accessible, allowing a higher frequency of samples to be collected and processed during an outbreak.
FMD virus is able to survive long periods of time in the environment in the right conditions (up to three months depending on environmental factors such as pH, temperature and relative humidity), so sampling areas where infected animals may have shed virus allows scientists to detect the presence of FMD even if the animals on the farm are no longer showing clinical signs.
The researchers say that novel surveillance techniques such as this can help support a robust response to outbreaks in FMD-free countries, and can also be implemented in endemic areas, such as parts of Asia, Africa and the Middle East, as part of surveillance programs to supplement current information about the spread of FMD.
Dr Claire Colenutt, who led the research at Pirbright said: "Current surveillance methods rely on the recognition of FMD infection in susceptible animals in addition to the collection of samples from the animals which requires veterinary expertise. In keeping the approach simple, samples can be taken by individuals without prior expertise, increasing the number of potential samples, and relieving pressure on veterinary services."
Photo: FMD. Dr. D. Denev
1243 farmers took part in the survey, which was held in partnership with the National Beef Association, British Dairying magazine, the relevant farming unions and the four eradication programmes.
Matt Yarnall from Boehringer said: "Reliance on veterinary input for this decision shows how valuable client discussion and guidance is. And further interrogation of the data shows other areas of BVD control where veterinary input could be extremely valuable.
"Too many producers are still holding onto PI animals in the hope they can be reared successfully and too many are making basic mistakes when it comes to herd biosecurity.
"The survey data revealed that 43% of farmers in Wales have identified a PI, but it is hugely concerning that almost half (42%) of these producers would not cull them immediately; these animals will go on to spread virus throughout the herd."
In Northern Ireland, 26 individual producers said they have kept a PI. "However, 20 had to be put down before reaching adulthood or had to be treated for other health conditions," said Matt. "Even in Scotland, with its well-established scheme, a small percentage of farmers claim they would isolate a PI and try to rear to slaughter and it was exactly the same in England."
Similarly, when it came down to the definition of a closed herd, Boehringer reports that there was significant lack of understanding about what this actually means.
Matt said: "Of the 62% of English producers that state they are closed herds, 2% rear calves away, 19% bring bulls in, 2% buy in heifers or cows and 1% purchase fattening stock.
"Obviously, this means they are not truly a closed herd and supports previous years when 23% and 24% of ‘closed herd’ producers in 2018 and 2017 respectively also brought bulls onto the farm.
"Add to this that 10% of these herds do not currently vaccinate so will not be protected against the BVD virus, and it is clear to see how vulnerable they are."
In Wales, 56% of herds were classified as closed, yet 12% still brought bulls on to the farm. Likewise in Northern Ireland, 60% of farms classified their herds as closed but 20% brought bulls on to the unit. The vast majority of Scottish herds also claimed to be closed, yet there were still inconsistencies around buying policy and biosecurity.
Matt said: "A certain lack of awareness about both the BVD Stamp it Out initiative and Gwaredu BVD schemes (43% English and 27% of Welsh producers respectively claimed to have no knowledge of these programmes) could actually be a positive for vets. It could be the perfect opportunity to engage in proactive conversations with clients, covering issues such as testing, PI removal and biosecurity."
Norbrook Laboratories has announced the addition of new indications to its Loxicom (meloxicam) products, two regarding its use in cats, and the other in calves.
Loxicom 5mg/ml solution for injection for dogs and cats is now indicated for the management of post-operative pain in cats. An injection given around the time of surgery can be followed up with a course of Loxicom 0.5 mg/ml oral suspension for cats. Alternatively, for cats where no follow-up oral treatment is possible, for example with feral cats, a larger dose of the injectable formulation can be given at the time of surgery.
Norbrook's EU Veterinary Advisor, Rebekah Dudek MRCVS, said: "Norbrook is pleased to be able to now offer vets two on-licence choices in relation to how they want to use their 5mg/ml meloxicam injection in cats. This gives vets the flexibility they need to be able to deal effectively with the wide variety of cases they see every day."
Loxicom 20mg/ml solution for injection for cattle, pigs and horses has now been licenced for the relief of post-operative pain following dehorning in calves.
Norbrook says that the use of a non-steroidal antiinflammatory drug (NSAID) alongside local anaesthetic has clear benefits for animal welfare, and that use at this time is also shown to offer economic benefits to the farmer, with increased food-conversion efficiency compared to untreated calves1.
Rebekah said: "Dehorning in calves has long been known as a painful procedure, with a negative impact on feed intake in the post-operative period. With our latest licence, Loxicom 20mg/ml can now be used for relief of this potentially economically important post-operative pain in calves."
Reference
The study, published in Nature Scientific Reports, investigated the effect of culling in the first three licensed badger cull areas – Gloucestershire, Somerset and Dorset – using data from 2013 to 2017.
Gloucestershire and Somerset saw reductions in bTB incidence rates in cull areas relative to comparison areas of 66 per cent and 37 per cent respectively after four years. In Dorset, there was no change in incidence rates in cull areas relative to comparison areas after two years, but incidence dropped by 55 per cent in the same period in the 2km buffer zone around the edge of the cull area. Matched comparison areas were similar but not identical.
James Russell, BVA Junior Vice President said: "These findings are encouraging and offer further evidence that badger culling can result in significant reductions in the number of new cases of TB in cattle. However, they come with the caveat that the data only relates to the first three cull areas, and the variability within these alone makes it too early to draw firm conclusions that culling will reduce incidence significantly in all 40 areas where it is now taking place.
"BVA’s expert working group is currently considering all aspects of disease control looking at cattle testing, removal of reactors, compensation and control in other farmed animals as well as the culling and vaccination of badgers. The group will consider this additional evidence as we develop our new policy on bTB.
"We continue to support a comprehensive and evidence-based approach to tackling bTB, including the use of badger culling where there is a demonstrated need and where it is done safely, humanely and effectively as part of a comprehensive strategy.
"The best way of halting the spread of this devastating disease is enhancing our understanding of bTB and applying that evidence to the eradication process.”
Centaur has launched a new service on the MyCentaur website which allows for 24-hour ordering from any broadband enabled computer.
A secure practice shopping list with controlled staff access to ordering and management information enables practices to safely control any buying.
According to the company, a key feature of the website is that any orders placed on line by 9pm will be delivered the following day, which gives practices even greater flexibility on ordering times over any existing vet wholesaling ordering service. As well as greater convenience, a financial benefit in using this method of ordering is that all on-line orders attract an additional two per cent discount.
The new code is one of a series of welfare codes currently being reviewed and updated by the Department for Environment, Food and Rural Affairs (Defra) following recent consultations.
BVA President John Fishwick said: "We warmly welcome these updates and we are particularly pleased to see the vital role the veterinary profession plays in maintaining poultry welfare recognised throughout the new code.
"We are also delighted to see the benefits of veterinary surveillance systems highlighted, with owners and keepers encouraged to use local and national disease surveillance sources to better understand poultry disease patterns and their local health and welfare landscape. This was a key element in our joint consultation response and reflects BVA’s recently published Position on veterinary scanning surveillance (animal health and disease monitoring).
"We are also pleased to see signposting within the Code of Practice to the Humane Slaughter Association’s Code of Practice for the Disposal of Chicks in Hatcheries, which outlines in detail information about humane methods of killing and good practice.
"The British poultry industry has some of the highest welfare standards in the world and the veterinary profession is fully committed to working with Defra on further enhancing animal welfare codes to reflect best industry practice."
Photo: Flock of Chickens (Gallus gallus domesticus) Roaming Freely in Front of Chicken Sheds on a Farm in the Rural Village of Chenson, Devon. Shutterstock / Peter Turner Photography
The ioLight microscope fits in a jacket pocket and the company says it is both simple to use and robust. It unfolds to record and share 5MP still images and real time HD video at a magnification of x200 on an iPad Air. The resolution is 1 micron or 1/1,000 mm, powerful enough to see the structure of plant and animal cells.
The microscope uses standard microscope slides and has adjustable top and bottom illumination for use on both biological and opaque samples.
Iolight says it is particularly good for live samples which deteriorate on the journey back to the lab, and it works anywhere, even without a WiFi or mobile phone network.
Andrew Monk, who founded ioLight with business partner Richard Williams, said: "It takes just a couple of minutes to get a great image on the microscope, anywhere from a river bank to a factory floor. This makes microscopy simpler for everyone, from experienced professionals to student scientists."
The ioLight microscope can be ordered now from www.iolight.co.uk, priced at £840 including VAT.
Forte developed the new solution alongside Professor Gayle Hallowell, Professor of Veterinary Internal Medicine and Critical Care at the School of Veterinary Medicine and Science, University of Nottingham.
The company says Hydrafast delivers ideal levels of sodium and glucose. It also contains glycine, an amino acid, acetate, propionate and citrate.
Professor Hallowell said: “This new ORS formula for calves is both practical and research-based, and should address what we know calves need when they have diarrhoea. It provides nutrition as well as an optimal electrolyte balance.”
Hydrafast comes in sachets of 133g. Each box of Hydrafast contains 24 sachets.
Hydrafast is available now from all major veterinary wholesalers, or direct from Forte Healthcare Ltd.
For more information contact your Forte Territory Manager, email enquiries@fortehealthcare.com or visit: www.fortehealthcare.com/product/hydrafast/
MSD Animal Health has obtained regulatory approval in 21 European countries, including the UK, for Cobactan LA 7.5% (cefquinome) - a new-generation, injectable antimicrobial for the treatment of swine respiratory disease (SRD).
Raul Berro DVM, global marketing director swine at MSD Animal Health said: "Cobactan LA 7.5% is a long-acting version of our highly effective Cobactan 2.5%. Its longer duration of action means greater compliance for swine producers with fewer injections and less stress to the animals, without sacrificing performance."
According to the company, the long-acting antibiotic formulation is effective against three major SRD pathogens in growing and finishing pigs - Actinobacillus pleuropneumoniae, Haemophilus parasuis and Pasteurella multocida. Considered the most important threat to the swine industry worldwide, SRD causes increased mortality, decreased weight gain and increased feed consumption.
Cobactan LA 7.5% requires two intramuscular injections 48 hours apart, compared to Cobactan 2.5%, which requires three daily injections. The recommended dose rate is 1 mL (3 mg cefquinome) per 25 kg bodyweight. The product isavailable in 50-ml, 100-ml and 250-ml glass vials.
Raul aded: "COBACTAN LA 7.5% also has a short withdrawal period of seven days. This makes the injectable product also safe to use throughout the finishing period for the treatment of SRD."
MSD adds that the use of COBACTAN LA 7.5% should be according to established responsible use guidelines and strictly according to the label instructions where specific restrictions apply to this class of antibiotics.
For more information, contact your local MSD Animal Health representative or go to www.msd-animal-health.com.
The decision comes after 13 dead wild birds were confirmed to have the virus in Warwickshire.
Last week 17 wild birds were tested positive in Dorset and 31 infected birds have now been identified at the Dorset site. At that time Defra responded by putting a local prevention zone in place and, now it is known the disease is not isolated to the Dorset site, the prevention zone has been extended across the country as a precautionary measure.
The prevention zone means bird keepers across the country must:
Those keepers who have more than 500 birds will need to take extra biosecurity measures that include restricting access to non-essential people, changing clothing and footwear before entering bird enclosures and cleaning and disinfecting vehicles.
The birds in Warwickshire are still being tested but it is expected that it will be the same H5N6 strain of bird flu that was found in the wild birds in Dorset and has been circulating wild birds across Europe. Public Health England have advised the risk to public health is very low with the Food Standards Agency also offering reassurance that bird flu does not pose a food safety risk for UK consumers. Defra has confirmed that the H5N6 strain is different to the strains which affected people in China last year.
Although it does not represent a threat to public, it is highly infectious and deadly to birds.
British Veterinary Association (BVA) President John Fishwick said: "I’d encourage vets to reassure their clients that this strain of Avian Influenza poses a very low risk to public health and the food chain. However, there is clearly a need to try to contain further spread of the disease, which has almost certainly come from migratory birds, and vets and poultry owners should follow the new prevention zone measures and remain vigilant for signs of bird flu."
British Veterinary Poultry Association (BVPA) President Phil Hammond added: "It’s really important that all bird keepers heed biosecurity advice issued by Defra, and maintain the highest biosecurity standards. Any suspicion of Avian Influenza should be reported to the APHA as soon as possible."
Up-to-date advice and guidance on Avian Influenza is available on the Gov.UK website, including how to spot it, what to do if you suspect it, and measures to prevent it:
https://www.gov.uk/guidance/avian-influenza-bird-flu#about-avian-influenza
For further advice on Avian Influenza contact the Defra Helpline on 03459 33 55 77.
Photo: Wild Birds, Shutterstock / aDam Wildlife
The aim of the survey, which closes on 16th June, is to recognise and help raise awareness of the multiple challenges faced by veterinary surgeons undertaking roles for Government as a distinct subset of the veterinary profession.
The Association of Government Veterinarians says that following the survey, it'll be producing a report which identifies issues which affect government vets' wellbeing, identifies existing tools to promote wellbeing within Government and considers developing new ones if necessary. It will also consider best practice and any gaps in the wellbeing services currently available that vets in Government roles would benefit from.
To take part in the survey, visit: https://www.surveymonkey.co.uk/r/vetswellbeing
You can read more about the survey here: https://vets.blog.gov.uk/2018/04/06/how-are-you-feeling-association-of-government-vets-wellbeing-survey-launched/
Photo: Christine Middlemiss introduces the survey.
Intervet/Schering-Plough Animal Health has announced the launch of Nuflor Minidose - a 50% more concentrated, but less viscous solution of its proven Nuflor antibiotic.
Nuflor Minidose is licensed for the treatment and prevention of bacterial BRD. Intervet/Schering-Plough Animal Health livestock veterinary adviser Rosemary Booth MRCVS said: "It delivers all the rapid efficacy entrusted in Nuflor, but at a lower volume. Whereas a 20ml dose of Nuflor will treat a 150kg animal, the same volume of Nuflor Minidose will cover a 225kg beast. Compared with Nuflor, the new Minidose formulation is easier to administer delivering a less viscous florfenicol solution, with a 62% improvement in viscosity at 15°C and 59% at 5°C."
Rosemary added that Nuflor Minidose is effective against the main bacterial causes of pneumonia: P. multocida, M. haemolytica and H. somni. "Florfenicol is the only antibiotic offering 100% sensitivity to these three key BRD causes in recent trials and its kill effect also ensures that within 24 hours bacteria levels are low enough to prevent any re-growth."
She also pointed out that the new, more concentrated florfenicol solution presents vets with an improved batch treatment option for controlling BRD considering Nuflor is recognised as an effective metaphylactic
"Batch treatment prevents BRD from spreading. Trials with Nuflor have demonstrated the benefit of metaphylactic batch treatment of sick calves in a pen once at least 20% of the animals exhibit disease symptoms. Nuflor was significantly more efficacious than a control in preventing the spread of BRD in healthy calves exposed to infected animals," she explains.
"The bacteria responsible for BRD are found in the respiratory tract of healthy cattle and stress or a greater pathogen load - such as exposure to sick calves - can easily trigger disease. BRD bacterial numbers can double every 30 minutes and in 24 hours, one bacterium can multiply to billions. Batch treatment kills the bacteria before they multiply, release toxins and cause permanent lung damage."
New Nuflor Minidose is licensed for injection subcutaneously for the prevention of BRD at a dose rate of 4ml/45kg and has a 64-day meat withdrawal period.
The Royal College of Veterinary Surgeons (RCVS) has clarified the legal position regarding the disbudding of goats, following recent media reports concerning undercover filming on UK goat farms.
The carrying out of any activity which amounts to veterinary surgery is restricted to veterinary surgeons unless there is a suitable exemption that allows other people to do it. The removal of the horn-bud of goats (disbudding) is considered veterinary surgery under the provisions of the Veterinary Surgeons Act 1966 (the Act).
Schedule 3 of the Act provides certain exemptions to the restriction on carrying out veterinary surgery, such as those allowing veterinary nurses and student veterinary nurses to undertake any medical treatment or any minor surgery (not involving entry into a body cavity) in certain circumstances. However, Schedule 3 specifically provides that these exemptions do not allow non-veterinary surgeons to undertake the disbudding of goats, except the trimming of the insensitive tip of an in-growing horn which, if left untreated, could cause pain or distress.
There are no other Exemption Orders covering the disbudding of goats and therefore this procedure may only be undertaken by veterinary surgeons.
The Mutilations (Permitted Procedures) (England) Regulations 2007, the Mutilations (Permitted Procedures) (Wales) Regulations 2007 and the Prohibited Procedures on Protected Animals (Exemptions) (Scotland) Regulations 2007 all include disbudding of goats as a procedure which can be carried out for non-therapeutic reasons. However, this secondary legislation is subject to the restrictions in the Veterinary Surgeons Act 1966 and therefore disbudding of goats is restricted to veterinary surgeons.The Welfare of Animals (Permitted Procedures By Lay Persons) Regulations (Northern Ireland) 2012 currently include disbudding of goats as a procedure which may be carried out by non-veterinary surgeons. However, the Veterinary Surgeons Act 1966 applies to Northern Ireland and the Regulations are scheduled to be amended later in 2012. This will make it clear that only veterinary surgeons may disbud goats in the UK.
The secondary legislation in the UK does not explicitly require anaesthetic to be administered when disbudding goats. However, disbudding should be carried out by veterinary surgeons in accordance with good practice and in such a way as to minimise pain and suffering caused to the animal, which should include use of an anaesthetic.
In summary, only a veterinary surgeon may undertake the disbudding of goats and due to the nature of the procedure, veterinary surgeons disbudding goats should administer anaesthetic.
An impurity was detected during stability monitoring. The impurity was isolated and the best estimate of identity indicated that the impurity is carprofen related.
The problem affects a limited number of batches and is identifiable through quality control testing. The concentration of the process impurity does not increase over time.
This recall is for the following batches only:
Norbrook is contacting wholesale dealers and veterinary surgeons to examine inventory and quarantine products subject to this recall.
For further information regarding the recall, contact Gary Mckee on 0044 2830 264435 or by email: gary.mckee@norbrook.co.uk
Sedaxylan 20 mg/ml contains the short acting alpha-2 agonist xylazine and is licensed for I/V administration.
It is also licensed for I/M administration in cattle; it has zero milk withdrawal and short one day meat withdrawal and sedation occurs in cattle within two minutes I/V and five to 10 minutes I/M.
Sedaxylan 20 mg/ml joins Dechra’s Nerfasin vet 100 mg/ml solution in the company’s anaesthesia and sedation range. Nerfasin vet also contains xylazine and is licensed for I/V administration for sedation and premedication prior to general anaesthesia in horses and cattle.
Alana McGlade, national sales manager at Dechra, said: “Dechra offers a comprehensive range of anaesthesia and sedation products allowing vets to customise protocols to the individual animal.
"Sedaxylan 20mg/ml and Nerfasin vet 100 mg/ml solution provide vets with flexible and convenient dosing options.”
Both Sedaxylan 20 mg/ml and Nerfasin vet 100 mg/ml are available in 25ml vials.
For more information, talk to your Dechra territory sales manager.
www.dechra.co.uk.
The intranasal vaccine can be administered to calves from one week old. It reduces the clinical signs of respiratory disease and viral shedding from infection with Bovine Respiratory Syncytial Virus (BRSV) and Parainfluenza-3 Virus (Pi3V).
MSD says that no other UK-licensed BRD vaccine can be administered earlier in life, and claims the vaccine delivers the fastest on-farm protection, with an onset of immunity after administration of 5 days for BRSV and 7 days for Pi3V. Duration of immunity is 12 weeks for both viruses.
MSD Animal Health livestock veterinary adviser Dr Kat Baxter-Smith said: "Having this early life calf pneumonia vaccine available in single dose vials will give farmers more practical leeway to be able to vaccinate vulnerable young calves from as young as a week of age, rather than delaying administration until a batch of calves are available. We know that early-age protection of young calves through intranasal vaccination can help prevent pneumonia and positively impact a beef or dairy calf’s productive future".
The new single dose vials are supplied in packs of five, complementing the five dose vials already available.
For further information, contact your MSD account manager.
BSAVA Summit will take place from 16-17 December 2019 at the Royal College of Physicians in London and will involve a series of high-profile keynote speakers and interactive workshops.
The Association says the event will deliver CPD differently to other veterinary meetings, with most sessions run as facilitated workshops to enable delegates to lead and shape discussions.
Confirmed facilitators include RCVS CEO Lizzie Lockett, BEVA President Renate Weller, Director of Clinical Research and Excellence in Practice at VetPartners Rachel Dean and Small Animal Medicine Specialist and Advanced Practitioner in Veterinary Cardiology Dr Kit Sturgess. Each day delegates can choose three out of a total of five workshops. Online forums will be used in the run up to BSAVA Summit to develop ideas and thinking for the workshops before the event.
Day one will focus on ‘The Profession Today’ and topics will include workforce issues, telemedicine, specialism, the future of advanced practitioners and regulation of the profession.
Day two will explore the future of ‘The Profession Tomorrow’ with topics including communication, over-diagnosis, over-treatment and innovation.
On the Monday evening delegates, speakers and facilitators will be able to network at a drinks reception in the library at the Royal College of Physicians.
BSAVA President Sue Paterson said: "We have launched BSAVA Summit to address the rising demand for a space to debate important topics, challenge mindsets and question accepted benchmarks. Following feedback from our members and the profession, Summit will revolutionise veterinary conference norms with a free-flow approach to champion active debate, discussion and reflection.
"There is a growing need to tackle some of the ethical and professional problems that face vets today such as over diagnosis, the role of specialists in practice, and research in practice. Importantly, the format of the discussion forums means that whilst the debate is led by a facilitator, the delegates will drive the agenda to arrive at stimulating and satisfying outcomes. It has been designed to fit with the new outcomes-based approach proposed by the RCVS where veterinary professionals are encouraged to plan their CPD, do their CPD and reflect on what they have learnt.
"The delegates are the key to the event, and Summit should attract people who want to be involved, want to input, want to make a difference and want to help drive the profession forward. I already have people eagerly emailing me wanting news of when the registration goes live.
"Summit aims to help delegates take a hard look at the way they work. Our aim is for each delegate to set themselves personal goals and we will be following up in 3 months to see if they have achieved them."
The BSAVA says that although the Summit is primarily targeted at experienced small animal practitioners, all vets, including equine and large animal practitioners, are welcome to attend.
The full programme will be available and registration will open online on 17th June. BSAVA members will have an opportunity to book advance tickets, with general sale opening two weeks later.
For further information visit www.bsavasummit.com.
Eurovet Animal Health has launched Marbiflox 10%, a new marbofloxacin preparation for the treatment of respiratory infections in cattle and pigs.
Eurovet says the product can be used flexibly to provide a single dose treatment, with a concentration-dependent effect and a relatively short withdrawal period. Marbiflox can be administered intravenously, subcutaneously or intramuscularly in cattle or intramuscularly in pigs.
The main indications, with reference to good prescribing practice, are for the treatment of respiratory infections caused by sensitive strains of Pasteurella multocida, Mannheimia haemolytica, and Histophilus somni and acute forms of mastitis induced by marbofloxacin-sensitive Escherichia coli strains, during lactation. In pigs the main indication is in the treatment of MMA (metritis mastitis agalactia syndrome).
Further information about Marbiflox and the complete Eurovet range of products is available from Eurovet Animal Health. www.eurovet-ah.co.uk/.
The Health Products Regulatory Authority (HPRA) has also granted a marketing authorisation in exceptional circumstances (Article 25, 26 EU Reg 2019/6) for Bultavo 3 in Ireland.
The company says that so far, more than 40 million doses of Bultavo 3 have been distributed in Europe to help limit the spread of BTV-3.
Boehringer points to a recent field study published by the German reference laboratory Friedrich-Loeffler-Institut (FLI), which showed that vaccination of sheep and cattle with Bultavo 3 induces immunity against the virus1.
According to the study, animals vaccinated with Bultavo 3 consistently showed evidence of a protective antibody response to BTV-3, although animals vaccinated with other BTV-3 vaccines did not1.
Boehringer says it is now compiling the data needed to obtain a full marketing authorisation in accordance with Article 8 of EU Regulation 2019/6.
Speaking at the MSD Animal Health sponsored National Mastitis Panel, David said that more widespread understanding of the issues is urgently required particularly amongst farmers and cattle vets if real progress is to be made.
David said: "There are some notable examples of veterinary practices that have worked with their clients to eliminate the use of CIAs. These are the exceptions, but they illustrate what is possible. As an industry, we need to speed up the rate of change and make a concerted effort to ensure more responsible use of antibiotics becomes the norm, sooner rather than later."
David quoted the British Cattle Veterinary Association (BCVA) position on the responsible use of medicines, which includes the recommendation of minimal use of third and fourth generation cephalosporins, fluoroquinalones and colistin, with these CIAs being limited to use where it has been demonstrated by sensitivity testing that they are the only suitable option to avoid unnecessary suffering.
"There has been agreement on this position amongst the veterinary associations, farmer organisations and milk buyers, but there needs to be more widespread awareness at producer level, particularly within the vet and farmer relationship.
"Farms with a robust herd health plan, where challenges are reduced, will be in the best position to minimise use of CIAs. This takes time and is most effective where there is good cooperation between the farm and its veterinary practice.
"Achieving a significant reduction in the use of CIAs voluntarily will not only minimise the likelihood of disruptive and potentially punitive legislation but will put our cattle industry on the front foot and strengthen its position in global markets."